Holen Sie sich die Stockscreener-App
31.38
1.00%
0.3218
Schlusskurs vom Vortag:
$31.06
Offen:
$31.77
24-Stunden-Volumen:
1.05M
Relative Volume:
1.12
Marktkapitalisierung:
$2.09B
Einnahmen:
$1.55M
Nettoeinkommen (Verlust:
$-258.76M
KGV:
-8.0563
EPS:
-3.8953
Netto-Cashflow:
$-213.66M
1W Leistung:
+6.41%
1M Leistung:
+6.59%
6M Leistung:
+18.92%
1J Leistung:
+98.80%
1-Tages-Spanne:
$30.88
$32.32
1-Wochen-Bereich:
$28.41
$32.61
52-Wochen-Spanne:
$14.40
$34.52
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
31.36 | 2.07B | 1.55M | -258.76M | -213.66M | -3.8953 |
VRTX
Vertex Pharmaceuticals Inc
|
433.53 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.09 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.56 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.57 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Underweight |
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Celldex closes $345 million stock offering By Investing.com - za.investing.com
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN
Celldex Therapeutics Completes $345 Million Public Offering of Common Stock - Quiver Quantitative
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - marketscreener.com
Celldex sells nearly 11.9M shares, raises $345M in stock deal - Stock Titan
Celldex Therapeutics announces public offering of common stock - MSN
Celldex Therapeutics, Inc. (CLDX) Options Chain - Yahoo! Finance Canada
JPMorgan Chase & Co. Sells 49,046 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Announces Pricing of $300 Million Public Offering of Common Stock - Sahm
Celldex Therapeutics stock falls on equity offering - Investing.com
Celldex Therapeutics stock falls on equity offering By Investing.com - Investing.com Canada
Celldex prices $300 million stock offering at $29 per share By Investing.com - au.investing.com
Celldex Therapeutics offers 10,345,000 shares of common stockSEC filing - marketscreener.com
Celldex Therapeutics (NASDAQ: CLDX) raises ~$282M net in $29 follow-on offering - Stock Titan
Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Celldex shares plunge after dumping $300 million stock deal - gurufocus.com
Celldex Announces Major Underwritten Public Equity Offering - TipRanks
Celldex Therapeutics Inc (TCE2.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celldex Therapeutics Prices $29 Share Sale, Expects $282 Million Net From Underwritten Offering - TradingView
Celldex (NASDAQ: CLDX) raises $300M in new common stock sale - Stock Titan
Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? - Yahoo Finance
Celldex launches public offering of common stock By Investing.com - za.investing.com
Celldex Therapeutics Inc (TCE2.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celldex Announces $300 Million Public Stock Offering - National Today
Celldex Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Celldex prices $300 million stock offering at $29 per share - investing.com
Celldex lines up $300M for drug launch prep and pipeline work - Stock Titan
Celldex announces pricing of $300 million public offering of common stock - marketscreener.com
Celldex announces proposed public offering of common stock - marketscreener.com
Celldex Announces Proposed Public Offering of Common Stock - bitget.com
Celldex Therapeutics (NASDAQ: CLDX) files prospectus supplement for common stock offering - Stock Titan
Celldex turns to stock sale to fund drug launch prep and pipeline - Stock Titan
CLDX PE Ratio & Valuation, Is CLDX Overvalued - Intellectia AI
STOK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Earnings Report: What makes Celldex Therapeutics Inc stock attractive today2026 Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Portfolio Recap: Does Celldex Therapeutics Inc stock benefit from AI growth2026 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn
A Look At Celldex Therapeutics (CLDX) Valuation As Shares Show Renewed Momentum - simplywall.st
Will Celldex Therapeutics Inc stock hit new highs in YEARQuarterly Growth Report & Expert Curated Trade Ideas - baoquankhu1.vn
Celldex Therapeutics presents positive phase 2 data for barzolvolimab in CSU, ColdU, and SD - marketscreener.com
Celldex reports quality of life gains in urticaria trials - Investing.com
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 - Yahoo Finance
Celldex reports quality of life gains in urticaria trials By Investing.com - Investing.com Canada
Vanguard discloses 0 ownership in Celldex (CLDX) after realignment - stocktitan.net
Will Celldex Therapeutics Inc benefit from government policy2026 Risk Factors & High Accuracy Buy Signal Tips - baoquankhu1.vn
Mizuho Initiates Coverage of Celldex Therapeutics (CLDX) with Outperform Recommendation - MSN
Celldex Therapeutics stock hits 52-week high at 32.8 USD By Investing.com - au.investing.com
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Celldex Therapeutics Inc-Aktie (CLDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PEPIN RONALD | SR. VP & CBO |
Dec 15 '25 |
Option Exercise |
5.47 |
19,333 |
105,714 |
20,097 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Dec 04 '25 |
Sale |
29.09 |
4,166 |
121,210 |
30,796 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):